Labopharm Inc. today announced that its NDA for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. FDA. The action date under the Prescription Drug User Fee Act (PDUFA) is July 18, 2009.
The details can be read here.
No comments:
Post a Comment